Novel Applications of Nanotechnology in Diagnosis and Treatment of Neurological Disorders
Main Article Content
Abstract
The prevalence of neurological disorders with unknown causes is rising, includes well-researched conditions like Parkinson's, Alzheimer's, multiple sclerosis, Schizophrenia, cerebrovascular diseases and stroke. Consequently, focus has shifted to creating novel and efficient drug delivery devices that can transport drugs and have good brain bioavailability by Nano neurotechnology. Some of these issues have recently shown encouraging remedies due to use of nanoparticles in medicine delivery. In the diagnosis and treatment of various illnesses with drug and/or imaging agent efficacy, cellular uptake and selective transport to target organs frequently arise. Due to the BBB, a densely packed layer of endothelial cells that blocks foreign chemicals from entering the brain, neurodegenerative illnesses pose significant problems. Engineered nanomaterials, which are particles between 1 and 100 nm in size, are offering intriguing biomedical tools that may be able to overcome these issues because of their physico-chemical characteristics and the potential for multi-functionalization, which allows conferring variety of properties simultaneously, including the capacity to pass the blood-brain barrier. This study focuses on the most advanced nanomaterials for neuroprotection, neuronal tissue regeneration, and diagnostic imaging of the most prevalent neurodegenerative illnesses. The range of nanotechnologies that are readily available enables the nanoscale material with properties most suited to the therapeutic difficulties presented by a specific CNS illness. Clinical neuroscience's use of nanotechnology will depend on our capacity to combine it with our expanding knowledge of the molecular causes of CNS disorder. Finally, new nanotechnological methods are explored.
References
1. Costa, C. P., Moreira, J. N., Lobo, J. M. S., & Silva, A. C. (2021). Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharmaceutica Sinica B, 11(4), 925-940.
2. Ngowi, E. E., Wang, Y. Z., Qian, L., Helmy, Y. A. S. H., Anyomi, B., Li, T., ... & Ji, X. Y. (2021). The application of nanotechnology for the diagnosis and treatment of brain diseases and disorders. Frontiers in Bioengineering and Biotechnology, 9, 629832.
3. Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25. doi: 10.1016/j.nbd.2009.07.030
4. Alany, R. (2017). Solid state characterization, solid dispersions, solubility enhancement, drug dissolution drug release. 10.1080/10837450.2017.1275305
5. Rosenberg, G. A. (2012). Neurological diseases in relation to the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism, 32(7), 1139-1151.
6. Amani, H., Habibey, R., Shokri, F., Hajmiresmail, S. J., Akhavan, O., Mashaghi, A., et al. (2019). Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling. Sci. Rep. 9:6044. doi: 10.1038/s41598-019-42633-9
7. Hawkins BT, Davis TP (2005) The blood-brain barrier / neurovascular unit in health and disease. Pharmacol Rev 57:173–85
8. Aldossary, N. M., Kotb, M. A., and Kamal, A. M. (2019). Predictive value of early MRI findings on neurocognitive and psychiatric outcomes in patients with severe traumatic brain injury. J. Affect. Disord. 243, 1–7. doi: 10.1016/j.jad.2018.09.001.
9. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe.Mult Scler 2017; 23: 1123–1136.
10. Perrelli, A., Fatehbasharzad, P., Benedetti, V., Ferraris, C., Fontanella, M., De Luca, E., ... & Retta, S. F. (2021). Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM). Expert Opinion on Drug Delivery, 18(7), 849-876.
11. Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 04 2018;38 (2):208–211.
12. Abbott, N. J. (2013). Blood–brain barrier structure and function and the challenges for CNS drug delivery. Journal of inherited metabolic disease, 36, 437-449.
13. Abbott NJ, Friedman A (2012) Overview and introduction: the blood– brain barrier in health and disease. Epilepsia 53(Suppl 6:1–6).
14. Abbott NJ (1992) Comparative physiology of the blood–brain barrier. In: Bradbury MWB (ed) Physiology and pharmacology of the blood–brain barrier (Handbk Exp Pharmacol 103). Springer, Heidelberg, pp 371–396.
15. Velasco-Aguirre, C., Morales, F., Gallardo-Toledo, E., Guerrero, S., Giralt, E., Araya, E., & Kogan, M. J. (2015). Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approaches. International journal of nanomedicine, 4919-4936.
16. Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012). Nanoparticles as drug delivery systems. Pharmacological reports, 64(5), 1020-1037.
17. Aminu, N., Bello, I., Umar, N. M., Tanko, N., Aminu, A., & Audu, M. M. (2020). The influence of nanoparticulate drug delivery systems in drug therapy. Journal of drug delivery science and technology, 60, 101961.
18. .A.Z. Wilczewska, K. Niemirowicz, K.H. Markiewicz, H. Car, Nanoparticles as drug delivery systems, Rep. nih.gov/pubmed/23238461.
19. S. Bamrungsap, Z. Zhao, T. Chen, L. Wang, C. Li, T. Fu, W. Tan, Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system, Nanomedicine 7 (2012) 1253 1271,
20. Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., ... & Padmanabhan, P. (2018). Theranostic applications of nanoparticles in neurodegenerative disorders. International journal of nanomedicine, 5561-5576.
21. Begley DJ, Kreuter J. Do ultra-low frequency (ULF) magnetic fields affect the blood-brain barrier? In: Holick MF, Jung EG, editors. Biologic Effects of Light 1998. Boston, MA: Springer US; 1999:297–301.
22. Sweeney P, Park H, Baumann M, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6(1):6.
23. Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J. (2014). Insights into direct nose to brain delivery: current status and future perspective. Drug delivery, 21(2), 75-86.
24. Ying W. (2008). The nose may help the brain: intranasal drug delivery for treating neurological diseases. Future Neurol 3:1–4.
25. Torchilin VP. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24:1–16.
26. Wong HL, Wu XY, Bendayan R. (2012). Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64: 686–700.
27. Niu, X., Chen, J., & Gao, J. (2019). Nanocarriers as a powerful vehicle to overcome blood brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian journal of pharmaceutical sciences, 14(5), 480-496.
28. Ghosh, P., Bera, A., & De, P. (2021). Current status, challenges and future directions in the treatment of neurodegenerative diseases by polymeric materials. Journal of the Indian Chemical Society, 98(1), 100011.
29. Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020). Recent advancements of nanomedicine in neurodegenerative disorders the ranostics. Advanced Functional Materials, 30(35), 2003054.
30. Ambavkar A. and Desai N. D., Development and evaluation of in – situ gelling system for nasal drug delivery of an anti – epileptic drug, Indian Drugs, 2017, 54 (09), 83 – 85.
31. Palshetkar AD, Jadhav SS, Save ND, Khan AF, Desai ND. Formulation Design and Evaluation of Iloperidone Nanosuspensions for Nasal Delivery using Wet-milling Approach. Current Nanomedicine. 2025 Jun;15(3):294-307.
32. Manza Priyanka.M, Shinde Ujwala.A., Sheth Kalyani.M and Desai Namita. D (2021) In situ gels of Acylovir Nanoemulsions for improved delivery to the eye, Drug Delivery Letters, 11 (3), 265 - 273.
33. Sawant ND, Tatke PA, Desai ND. Optimization and Evaluation of Functionally Engineered Paliperidone Nanoemulsions for Improved Brain Delivery via Nasal Route. Molecular Pharmaceutics. 2025 Oct 7.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.